Immunology of Hodgkin Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 11944
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hodgkin Lymphoma (HL) is a cancer of lymph nodes and is commonly diagnosed in adolescents and young adults. It is characterized by a minority of tumor cells, called Hodgkin and Reed–Sternberg (HRS) cells, that are surrounded by a large number of reactive immune cells. The HRS cells originate from germinal center B-cells and are highly aberrant. It is hard to understand how they can develop within lymph nodes, especially in young and otherwise healthy individuals. This is even more apparent in cases in which the immunogenic Epstein–Barr-virus (EBV) is present in the tumor cells. Not only do (precursor) HRS cells escape from a multitude of anti-tumor immune responses, they even shape and hijack the tumor microenvironment (TME) for their own benefit. This may explain why novel treatments like immune checkpoint inhibitors that target the TME are highly effective in HL. However, despite advancements in the past decades, much has still to be learned on the immunology of HL and its role in susceptibility, pathogenesis, and treatment response.
You are invited to contribute original research to this Special Issue on the Immunology of Hodgkin Lymphoma. The main theme is the cross-talk between (cells of) the TME and (precursor) HRS cells. Manuscripts on immunology related blood biomarkers and genetic susceptibility are also invited.
Dr. Arjan Diepstra
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hodgkin Lymphoma
- immunology
- tumor microenvironment
- Epstein–Barr virus
- pathogenesis
- susceptibility
- biomarkers